Induced Pluripotent Stem Cell-Based Cancer Vaccines

por Ouyang, Xiaoming, Telli, Melinda L., Wu, Joseph C.
Publicado 2019

Qualitative and Quantitative Image-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer

por Golden, Daniel I., Lipson, Jafi A., Telli, Melinda L., Ford, James M., Rubin, Daniel L.
Publicado 2018

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured dissem...

por Deng, Glenn, Krishnakumar, Sujatha, Powell, Ashley A, Zhang, Haiyu, Mindrinos, Michael N, Telli, Melinda L, Davis, Ronald W, Jeffrey, Stefanie S
Publicado 2014

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

por Doherty, Mary R., Cheon, HyeonJoo, Junk, Damian J., Vinayak, Shaveta, Varadan, Vinay, Telli, Melinda L., Ford, James M., Stark, George R., Jackson, Mark W.
Publicado 2017

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes

por Gruber, Joshua J., Afghahi, Anosheh, Timms, Kirsten, DeWees, Alyssa, Gross, Wyatt, Aushev, Vasily N., Wu, Hsin-Ta, Balcioglu, Mustafa, Sethi, Himanshu, Scott, Danika, Foran, Jessica, McMillan, Alex, Ford, James M., Telli, Melinda L.
Publicado 2022

Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer

por Ransohoff, Julia D., Ritter, Victor, Purington, Natasha, Andrade, Karen, Han, Summer, Liu, Mina, Liang, Su-Ying, John, Esther M., Gomez, Scarlett L., Telli, Melinda L., Schapira, Lidia, Itakura, Haruka, Sledge, George W., Bhatt, Ami S., Kurian, Allison W.
Publicado 2023

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rati...

por Isakoff, Steven J, Puhalla, Shannon, Domchek, Susan M, Friedlander, Michael, Kaufman, Bella, Robson, Mark, Telli, Melinda L, Diéras, Véronique, Han, Hyo Sook, Garber, Judy E, Johnson, Eric F, Maag, David, Qin, Qin, Giranda, Vincent L, Shepherd, Stacie P
Publicado 2017

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

por Litton, Jennifer K, Beck, J Thaddeus, Jones, Jason M, Andersen, Jay, Blum, Joanne L, Mina, Lida A, Brig, Raymond, Danso, Michael, Yuan, Yuan, Abbattista, Antonello, Noonan, Kay, Niyazov, Alexander, Chakrabarti, Jayeta, Czibere, Akos, Symmans, William F, Telli, Melinda L
Publicado 2023

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

por Vahdat, Linda T., Schmid, Peter, Forero-Torres, Andres, Blackwell, Kimberly, Telli, Melinda L., Melisko, Michelle, Möbus, Volker, Cortes, Javier, Montero, Alberto J., Ma, Cynthia, Nanda, Rita, Wright, Gail S., He, Yi, Hawthorne, Thomas, Bagley, Rebecca G., Halim, Abdel-Baset, Turner, Christopher D., Yardley, Denise A.
Publicado 2021

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

por Telli, Melinda L., Tolaney, Sara M., Shapiro, Geoffrey I., Middleton, Mark, Lord, Simon R., Arkenau, Hendrik Tobias, Tutt, Andrew, Abramson, Vandana, Dean, Emma, Haddad, Tufia C., Wesolowski, Robert, Ferrer-Playan, Jordi, Goddemeier, Thomas, Grombacher, Thomas, Dong, Jennifer, Fleuranceau-Morel, Patricia, Diaz-Padilla, Ivan, Plummer, Ruth
Publicado 2022

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

por Turner, Nicholas C., Laird, A. Douglas, Telli, Melinda L., Rugo, Hope S., Mailliez, Audrey, Ettl, Johannes, Grischke, Eva-Maria, Mina, Lida A., Balmaña, Judith, Fasching, Peter A., Hurvitz, Sara A., Hopkins, Julia F., Albacker, Lee A., Chelliserry, Jijumon, Chen, Ying, Conte, Umberto, Wardley, Andrew M., Robson, Mark E.
Publicado 2023

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition

por Zhang, Haiyu, Cohen, Adam L, Krishnakumar, Sujatha, Wapnir, Irene L, Veeriah, Selvaraju, Deng, Glenn, Coram, Marc A, Piskun, Caroline M, Longacre, Teri A, Herrler, Michael, Frimannsson, Daniel O, Telli, Melinda L, Dirbas, Frederick M, Matin, AC, Dairkee, Shanaz H, Larijani, Banafshe, Glinsky, Gennadi V, Bild, Andrea H, Jeffrey, Stefanie S
Publicado 2014

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial

por Yap, Timothy A., Bardia, Aditya, Dvorkin, Michael, Galsky, Matthew D., Beck, J. Thaddeus, Wise, David R., Karyakin, Oleg, Rubovszky, Gábor, Kislov, Nikolay, Rohrberg, Kristoffer, Joy, Anil Abraham, Telli, Melinda L., Schram, Alison M., Conte, Umberto, Chappey, Colombe, Stewart, Ross, Stypinski, Daria, Michelon, Elisabete, Cesari, Rossano, Konstantinopoulos, Panagiotis A.
Publicado 2022

Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines

por Powell, Ashley A., Talasaz, AmirAli H., Zhang, Haiyu, Coram, Marc A., Reddy, Anupama, Deng, Glenn, Telli, Melinda L., Advani, Ranjana H., Carlson, Robert W., Mollick, Joseph A., Sheth, Shruti, Kurian, Allison W., Ford, James M., Stockdale, Frank E., Quake, Stephen R., Pease, R. Fabian, Mindrinos, Michael N., Bhanot, Gyan, Dairkee, Shanaz H., Davis, Ronald W., Jeffrey, Stefanie S.
Publicado 2012

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

por Schram, Alison M., Colombo, Nicoletta, Arrowsmith, Edward, Narayan, Vivek, Yonemori, Kan, Scambia, Giovanni, Zelnak, Amelia, Bauer, Todd M., Jin, Ning, Ulahannan, Susanna V., Colleoni, Marco, Aftimos, Philippe, Donoghue, Mark T. A., Rosen, Ezra, Rudneva, Vasilisa A., Telli, Melinda L., Domchek, Susan M., Galsky, Matthew D., Hoyle, Margaret, Chappey, Colombe, Stewart, Ross, Blake-Haskins, John A., Yap, Timothy A.
Publicado 2022

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

por Cruz, Cristina, Llop-Guevara, Alba, Garber, Judy E., Arun, Banu K., Pérez Fidalgo, José A., Lluch, Ana, Telli, Melinda L., Fernández, Cristian, Kahatt, Carmen, Galmarini, Carlos M., Soto-Matos, Arturo, Alfaro, Vicente, Pérez de la Haza, Aitor, Domchek, Susan M., Antolin, Silvia, Vahdat, Linda, Tung, Nadine M., Lopez, Rafael, Arribas, Joaquín, Vivancos, Ana, Baselga, José, Serra, Violeta, Balmaña, Judith, Isakoff, Steven J.
Publicado 2018

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

por Lenz, Lauren, Neff, Chris, Solimeno, Cara, Cogan, Elizabeth S., Abramson, Vandana G., Boughey, Judy C., Falkson, Carla, Goetz, Matthew P., Ford, James M., Gradishar, William J., Jankowitz, Rachel C., Kaklamani, Virginia G., Marcom, P. Kelly, Richardson, Andrea L., Storniolo, Anna Maria, Tung, Nadine M., Vinayak, Shaveta, Hodgson, Darren R., Lai, Zhongwu, Dearden, Simon, Hennessy, Bryan T., Mayer, Erica L., Mills, Gordon B., Slavin, Thomas P., Gutin, Alexander, Connolly, Roisin M., Telli, Melinda L., Stearns, Vered, Lanchbury, Jerry S., Timms, Kirsten M.
Publicado 2023